{"id":741512,"date":"2023-03-21T08:08:52","date_gmt":"2023-03-21T12:08:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"},"modified":"2023-03-21T08:08:52","modified_gmt":"2023-03-21T12:08:52","slug":"cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","title":{"rendered":"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023"},"content":{"rendered":"

\n– CEO Participating on Panel Hosted by Alzheimer\u2019s Drug Discovery Foundation –
\n<\/h2>\n
\n

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) — Cognition <\/strong><\/a>Therapeutics<\/strong><\/a>, Inc.<\/strong><\/a> (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE (COG0201; NCT03507790<\/a>) and Phase 1b SPARC (COG0105; NCT03493282<\/a>) studies with mild-to-moderate Alzheimer’s disease who were treated with either CT1812 or placebo. Results of this analysis identified biomarkers of CT1812 activity that replicated across these two independent studies and patient cohorts. These findings inform our understanding of the impact of CT1812 treatment on the network of biologic pathways associated with Alzheimer\u2019s disease progression. A detailed poster presentation (poster #P0407) will be made at the upcoming AD\/PD\u2122 2023: the International Conference on Alzheimer\u2019s & Parkinson\u2019s Diseases being held in Gothenburg, Sweden from March 28 to April 1, 2023.<\/p>\n

In addition, Lisa Ricciardi, CEO of Cognition Therapeutics will be participating in a panel hosted by the Alzheimer\u2019s Drug Discovery Foundation. The panel, \u201cEmerging Solutions: Novel Approaches to Alzheimer\u2019s Disease\u201d will take place in the Industry Symposium<\/a>, \u201cBuilding the Future: Novel Approaches and Innovations in Alzheimer\u2019s Research” being held on March 29, 2023 at 11:40am local time. The panelists will discuss the need for multiple novel approaches to address neurodegenerative diseases with an emphasis on the value of rigorous and biomarker-driven clinical trials to help implement this multipronged approach.<\/p>\n

\n Poster details<\/strong>:
Title:<\/u> Pharmacodynamic Effects of the S2R Modulator CT1812 in Alzheimer\u2019s Disease (AD) Patients Observed in a Meta-analysis of CSF Proteomes from SPARC and SHINE Part A
Authors:<\/u> Duong D, Waybright L, Pandey K, Lizama B, Mecca A, van Dyck C, Grundman M, Blennow K, Zetterberg H, Caggiano AO, Seyfried N, Hamby ME
Date\/Time:<\/u>\u00a0\u00a0 March 29, 2023 \u2013 April 1, 2023<\/p>\n

\n About CT1812<\/strong>
\n
CT1812 is an experimental orally delivered small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (\u03c3-2) receptor complex. The \u03c3-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with soluble beta amyloid (A\u03b2) oligomers, oxidative stress and other stressors. This damage to sensitive synapses can progress to a loss of synaptic function, which manifests as cognitive impairment and Alzheimer\u2019s disease progression. CT1812 is currently in development for mild-to-moderate Alzheimer\u2019s disease in the SHINE study (NCT03507790) and dementia with Lewy bodies in the SHIMMER study (NCT05225415).<\/p>\n

\n About Cognition Therapeutics, Inc.<\/strong>
\n
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs<\/a> in Alzheimer\u2019s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of \u03c3-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the \u03c3-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at http:\/\/cogrx.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our Phase 2 START study of CT1812, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, and cash runway,<\/em> involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d might,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201caim,\u201d \u201cseek,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the ongoing COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the \u201cRisk Factors\u201d section of our annual and quarterly reports filed the\u00a0Securities Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n

\n Contact Information:<\/strong>
\n
Cognition Therapeutics, Inc.
info@cogrx.com<\/a><\/p>\n

Aline Sherwood (media)
Scienta Communications
asherwood@scientapr.com<\/a><\/p>\n

Daniel Kontoh-Boateng (investors)
Tiberend Strategic Advisors, Inc.
dboateng@tiberend.com<\/a>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

– CEO Participating on Panel Hosted by Alzheimer\u2019s Drug Discovery Foundation – NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE (COG0201; NCT03507790) and Phase 1b SPARC (COG0105; NCT03493282) studies with mild-to-moderate Alzheimer’s disease who were treated with either CT1812 or placebo. Results of this analysis identified biomarkers of CT1812 activity that replicated across these two independent studies and patient cohorts. These findings inform our understanding of the impact of CT1812 treatment on the network of biologic pathways associated with Alzheimer\u2019s disease progression. A detailed poster presentation (poster #P0407) will … <\/p>\n

Continue reading “Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-741512","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– CEO Participating on Panel Hosted by Alzheimer\u2019s Drug Discovery Foundation – NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE (COG0201; NCT03507790) and Phase 1b SPARC (COG0105; NCT03493282) studies with mild-to-moderate Alzheimer’s disease who were treated with either CT1812 or placebo. Results of this analysis identified biomarkers of CT1812 activity that replicated across these two independent studies and patient cohorts. These findings inform our understanding of the impact of CT1812 treatment on the network of biologic pathways associated with Alzheimer\u2019s disease progression. A detailed poster presentation (poster #P0407) will … Continue reading "Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-21T12:08:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\\\/PD 2023\",\"datePublished\":\"2023-03-21T12:08:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\"},\"wordCount\":1165,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\",\"name\":\"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\\\/PD 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=\",\"datePublished\":\"2023-03-21T12:08:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\\\/PD 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","og_locale":"en_US","og_type":"article","og_title":"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Market Newsdesk","og_description":"– CEO Participating on Panel Hosted by Alzheimer\u2019s Drug Discovery Foundation – NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE (COG0201; NCT03507790) and Phase 1b SPARC (COG0105; NCT03493282) studies with mild-to-moderate Alzheimer’s disease who were treated with either CT1812 or placebo. Results of this analysis identified biomarkers of CT1812 activity that replicated across these two independent studies and patient cohorts. These findings inform our understanding of the impact of CT1812 treatment on the network of biologic pathways associated with Alzheimer\u2019s disease progression. A detailed poster presentation (poster #P0407) will … Continue reading \"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-21T12:08:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023","datePublished":"2023-03-21T12:08:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"},"wordCount":1165,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/","name":"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=","datePublished":"2023-03-21T12:08:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5MjA1MyM1NDcyMTk3IzIwODQ4NzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-to-present-proteomic-biomarker-analyses-from-clinical-studies-of-ct1812-in-patients-with-alzheimers-disease-at-ad-pd-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer\u2019s Disease at AD\/PD 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=741512"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741512\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=741512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=741512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=741512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}